Can-Fite BioPharma to Attend BIO International Convention
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Clinical Trial Progress: Can-Fite's lead drug candidate, Namodenoson, is currently undergoing a pivotal Phase III study for advanced hepatocellular carcinoma while completing a Phase IIa study in pancreatic cancer, indicating its potential in oncology and possibly opening new market opportunities for the company.
- New Drug Development: Piclidenoson, aimed at inflammatory diseases, is in a pivotal Phase III study for psoriasis and preparing for a Phase II study in the rare genetic disease Lowe Syndrome, further enriching the company's product pipeline.
- Strategic Partnership Opportunities: At the 2026 BIO International Convention, Can-Fite will hold partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization opportunities for its clinical-stage pipeline, which is expected to generate new revenue streams for the company.
- Market Potential Assessment: Can-Fite's A3 adenosine receptor platform technology has demonstrated a favorable safety profile in over 1,600 patients, and with approximately $20 million in licensing agreement revenues generated globally, it highlights the significant market potential in cancer and inflammatory disease treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CANF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CANF
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Can-Fite BioPharma to Attend BIO International Convention
- Clinical Trial Progress: Can-Fite's lead drug candidate, Namodenoson, is currently undergoing a pivotal Phase III study for advanced hepatocellular carcinoma while completing a Phase IIa study in pancreatic cancer, indicating its potential in oncology and possibly opening new market opportunities for the company.
- New Drug Development: Piclidenoson, aimed at inflammatory diseases, is in a pivotal Phase III study for psoriasis and preparing for a Phase II study in the rare genetic disease Lowe Syndrome, further enriching the company's product pipeline.
- Strategic Partnership Opportunities: At the 2026 BIO International Convention, Can-Fite will hold partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization opportunities for its clinical-stage pipeline, which is expected to generate new revenue streams for the company.
- Market Potential Assessment: Can-Fite's A3 adenosine receptor platform technology has demonstrated a favorable safety profile in over 1,600 patients, and with approximately $20 million in licensing agreement revenues generated globally, it highlights the significant market potential in cancer and inflammatory disease treatments.
See More
Can-Fite BioPharma Publishes Canine Osteoarthritis Study Results
- Publication of Findings: Can-Fite BioPharma published a study in the journal Frontiers in Veterinary Science regarding Piclidenoson's efficacy in treating canine osteoarthritis, demonstrating significant improvements in mobility and pain assessments at a dosage of 500 µg/kg BID, indicating its potential as an oral disease-modifying therapy.
- Clinical Data Validation: The study reported significant enhancements in Liverpool Osteoarthritis scores and reductions in pain as measured by the Visual Analog Scale (VAS), with no serious treatment-related adverse events, confirming the drug's favorable safety profile.
- Market Opportunity: Canine osteoarthritis is a prevalent chronic condition among dogs, with limited current treatment options; the development of Piclidenoson not only addresses this unmet need but also presents a potential revenue opportunity of up to $325 million from Can-Fite's collaboration with Vetbiolix.
- Strategic Collaboration Outlook: The Chief Scientific Officer of Can-Fite noted that the publication of these findings provides important external validation of Piclidenoson's therapeutic potential, further supporting the commercial prospects of their partnership with Vetbiolix, which is expected to drive growth in the veterinary market.
See More
Can-Fite BioPharma Reports Positive Clinical Data for Namodenoson
- Clinical Trial Results: Can-Fite's Phase 2a study for advanced pancreatic cancer shows over 30% of evaluable patients with stable disease, indicating potential clinical activity in a heavily pretreated population, which may provide durable treatment benefits for this difficult-to-treat group.
- Treatment Duration: Some patients in the study have been treated for over 16 months, with 35% remaining on therapy, reflecting not only the drug's good tolerability but also supporting the clinical necessity for continued development of namodenoson.
- Safety Analysis: The primary objective of the study was to assess the safety profile of namodenoson, which was found to be consistent with previous reports, with no new safety signals identified, further enhancing its potential application in other oncological diseases.
- Future Outlook: Can-Fite expects to release comprehensive efficacy analysis results, including progression-free survival and overall survival, in the coming months, which will provide crucial data support for the clinical development of namodenoson in pancreatic cancer.
See More
Can-Fite Signs Up to $325M Deal with Vetbiolix
- Clinical Trial Progress: Vetbiolix has completed enrollment of 118 dogs in the Phase 2 clinical trial of Piclidenoson, with top-line results expected in Q3 2026, which could significantly boost Can-Fite's revenue in the veterinary market if successful.
- Market Potential: The global canine osteoarthritis market is projected to reach approximately $3 billion by 2028, and Can-Fite's Piclidenoson is poised to become a safe and effective treatment option, addressing the growing demand for pet healthcare.
- Agreement Details: Under the agreement, Can-Fite is entitled to receive up to $325 million in upfront, milestone, and royalty payments, with Vetbiolix responsible for all development and regulatory activities, highlighting the depth and potential of their collaboration.
- Product Background: Piclidenoson is a novel A3 adenosine receptor agonist that has demonstrated excellent safety and efficacy in a Phase III trial for psoriasis, and it is expected to play a significant role in treating canine osteoarthritis in the future.
See More
Can-Fite Biopharma Reports FY 2025 Financial Results
- Declining Financial Performance: Can-Fite Biopharma reported a GAAP EPS of -$5.97 for FY 2025, indicating significant challenges in profitability that could impact investor confidence and future financing capabilities.
- Substantial Revenue Drop: The company generated revenue of $0.41 million, a 38.8% year-over-year decline, reflecting weak market demand for its products, which may lead to tighter funding for future R&D and operations.
- Improved Cash Position: As of December 31, 2025, Can-Fite had cash and cash equivalents and short-term deposits totaling $8.54 million, up from $7.88 million in 2024, demonstrating proactive liquidity management efforts.
- Uncertain Future Outlook: Despite the increase in cash reserves, the ongoing revenue decline and negative earnings situation may limit the company's growth potential, prompting investors to closely monitor subsequent strategic adjustments and market responses.
See More
Can-Fite BioPharma Reports 2025 Financial Results and Clinical Advances
- Clinical Trial Progress: Can-Fite's Phase 2a study in pancreatic cancer achieved its primary safety endpoint, with over 30% of patients alive at the last data cut-off, indicating potential efficacy and positive implications for patient survival.
- Successful Case in HCC: A patient with advanced hepatocellular carcinoma treated with Namodenoson has remained cancer-free for over nine years post-treatment, highlighting the drug's potential as a novel therapeutic option in liver oncology.
- Decline in Financial Performance: Can-Fite reported revenues of $405,000 for 2025, a 40% decrease year-over-year, primarily due to reduced advance payments under distribution agreements, reflecting challenges in revenue generation.
- Increased R&D Expenses: Research and development expenses rose to $6.69 million in 2025, a 16.26% increase, mainly driven by ongoing clinical trials for Namodenoson and Piclidenoson, demonstrating the company's commitment to advancing its drug pipeline.
See More
Can-Fite BioPharma to Attend BIO International Convention
- Clinical Trial Progress: Can-Fite's lead drug candidate, Namodenoson, is currently undergoing a pivotal Phase III study for advanced hepatocellular carcinoma while completing a Phase IIa study in pancreatic cancer, indicating its potential in oncology and possibly opening new market opportunities for the company.
- New Drug Development: Piclidenoson, aimed at inflammatory diseases, is in a pivotal Phase III study for psoriasis and preparing for a Phase II study in the rare genetic disease Lowe Syndrome, further enriching the company's product pipeline.
- Strategic Partnership Opportunities: At the 2026 BIO International Convention, Can-Fite will hold partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization opportunities for its clinical-stage pipeline, which is expected to generate new revenue streams for the company.
- Market Potential Assessment: Can-Fite's A3 adenosine receptor platform technology has demonstrated a favorable safety profile in over 1,600 patients, and with approximately $20 million in licensing agreement revenues generated globally, it highlights the significant market potential in cancer and inflammatory disease treatments.
See More
Can-Fite BioPharma Publishes Canine Osteoarthritis Study Results
- Publication of Findings: Can-Fite BioPharma published a study in the journal Frontiers in Veterinary Science regarding Piclidenoson's efficacy in treating canine osteoarthritis, demonstrating significant improvements in mobility and pain assessments at a dosage of 500 µg/kg BID, indicating its potential as an oral disease-modifying therapy.
- Clinical Data Validation: The study reported significant enhancements in Liverpool Osteoarthritis scores and reductions in pain as measured by the Visual Analog Scale (VAS), with no serious treatment-related adverse events, confirming the drug's favorable safety profile.
- Market Opportunity: Canine osteoarthritis is a prevalent chronic condition among dogs, with limited current treatment options; the development of Piclidenoson not only addresses this unmet need but also presents a potential revenue opportunity of up to $325 million from Can-Fite's collaboration with Vetbiolix.
- Strategic Collaboration Outlook: The Chief Scientific Officer of Can-Fite noted that the publication of these findings provides important external validation of Piclidenoson's therapeutic potential, further supporting the commercial prospects of their partnership with Vetbiolix, which is expected to drive growth in the veterinary market.
See More
Can-Fite BioPharma Reports Positive Clinical Data for Namodenoson
- Clinical Trial Results: Can-Fite's Phase 2a study for advanced pancreatic cancer shows over 30% of evaluable patients with stable disease, indicating potential clinical activity in a heavily pretreated population, which may provide durable treatment benefits for this difficult-to-treat group.
- Treatment Duration: Some patients in the study have been treated for over 16 months, with 35% remaining on therapy, reflecting not only the drug's good tolerability but also supporting the clinical necessity for continued development of namodenoson.
- Safety Analysis: The primary objective of the study was to assess the safety profile of namodenoson, which was found to be consistent with previous reports, with no new safety signals identified, further enhancing its potential application in other oncological diseases.
- Future Outlook: Can-Fite expects to release comprehensive efficacy analysis results, including progression-free survival and overall survival, in the coming months, which will provide crucial data support for the clinical development of namodenoson in pancreatic cancer.
See More
Can-Fite Signs Up to $325M Deal with Vetbiolix
- Clinical Trial Progress: Vetbiolix has completed enrollment of 118 dogs in the Phase 2 clinical trial of Piclidenoson, with top-line results expected in Q3 2026, which could significantly boost Can-Fite's revenue in the veterinary market if successful.
- Market Potential: The global canine osteoarthritis market is projected to reach approximately $3 billion by 2028, and Can-Fite's Piclidenoson is poised to become a safe and effective treatment option, addressing the growing demand for pet healthcare.
- Agreement Details: Under the agreement, Can-Fite is entitled to receive up to $325 million in upfront, milestone, and royalty payments, with Vetbiolix responsible for all development and regulatory activities, highlighting the depth and potential of their collaboration.
- Product Background: Piclidenoson is a novel A3 adenosine receptor agonist that has demonstrated excellent safety and efficacy in a Phase III trial for psoriasis, and it is expected to play a significant role in treating canine osteoarthritis in the future.
See More
Can-Fite Biopharma Reports FY 2025 Financial Results
- Declining Financial Performance: Can-Fite Biopharma reported a GAAP EPS of -$5.97 for FY 2025, indicating significant challenges in profitability that could impact investor confidence and future financing capabilities.
- Substantial Revenue Drop: The company generated revenue of $0.41 million, a 38.8% year-over-year decline, reflecting weak market demand for its products, which may lead to tighter funding for future R&D and operations.
- Improved Cash Position: As of December 31, 2025, Can-Fite had cash and cash equivalents and short-term deposits totaling $8.54 million, up from $7.88 million in 2024, demonstrating proactive liquidity management efforts.
- Uncertain Future Outlook: Despite the increase in cash reserves, the ongoing revenue decline and negative earnings situation may limit the company's growth potential, prompting investors to closely monitor subsequent strategic adjustments and market responses.
See More
Can-Fite BioPharma Reports 2025 Financial Results and Clinical Advances
- Clinical Trial Progress: Can-Fite's Phase 2a study in pancreatic cancer achieved its primary safety endpoint, with over 30% of patients alive at the last data cut-off, indicating potential efficacy and positive implications for patient survival.
- Successful Case in HCC: A patient with advanced hepatocellular carcinoma treated with Namodenoson has remained cancer-free for over nine years post-treatment, highlighting the drug's potential as a novel therapeutic option in liver oncology.
- Decline in Financial Performance: Can-Fite reported revenues of $405,000 for 2025, a 40% decrease year-over-year, primarily due to reduced advance payments under distribution agreements, reflecting challenges in revenue generation.
- Increased R&D Expenses: Research and development expenses rose to $6.69 million in 2025, a 16.26% increase, mainly driven by ongoing clinical trials for Namodenoson and Piclidenoson, demonstrating the company's commitment to advancing its drug pipeline.
See More
